This discussion emphasizes practical implementation. Freedland outlines how urologists and medical oncologists can collaborate to ensure timely therapy initiation and shares insights into patient- and ...
The discussion opens with an overview of the evolving management of high-risk non–muscle invasive bladder cancer (NMIBC) and introduces the session’s goals of reviewing the treatment landscape, recent ...
Nanopath's assay for cUTIs has received FDA breakthrough device designation, indicating its potential to significantly advance UTI diagnosis. The assay aims to deliver molecular results in 15 minutes, ...
Treatment intensification with ARPIs and chemotherapy has transformed mCSPC management, expanding the urologist's role in early treatment phases. Darolutamide is highlighted for its favorable safety ...
Panelists discuss how real-world comparisons of apalutamide and enzalutamide suggest survival trends influenced by tolerability, adherence, and patient selection rather than intrinsic drug differences ...
The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC. According to the authors, “ADVC001 is a novel PSMA ...
Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...
Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation. In this video, urologist Jonathan Henderson, MD, of Arkansas Urology in Little Rock, reflects on ...
In an interview at the 2025 LUGPA Annual Meeting, Stacy Loeb, MD, shared key takeaways from her session, “Current state of prostate cancer screening.” Loeb is a urologists at NYU Langone Health in New ...
In September 2024, the FDA granted an Orphan Drug Designation and a Rare Pediatric Disease Designation to YOLT-203 for PH1.
The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback